Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONZIP vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Moderate to moderately severe pain,Pain management in adults
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life: 3-4 hours for tramadol, 5-9 hours for M1 metabolite; clinically, dosing interval is 4-6 hours
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Tramadol: hepatic via CYP2D6 and CYP3A4 to active M1 metabolite; acetaminophen: hepatic via conjugation (glucuronidation, sulfation) and CYP2E1 (minor).
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
~60% renal (unchanged drug and glucuronide conjugates), ~35% fecal
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
~20% bound to plasma proteins (primarily albumin)
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
3.9 L/kg (tramadol), indicating extensive tissue distribution
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: 75% (immediate-release); extended-release: ~100% relative to immediate-release
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
For creatinine clearance (Cr Cl) 60-89 m L/min: no adjustment. For Cr Cl 30-59 m L/min: reduce dose by 30% (e.g., start 70 mg daily). For Cr Cl 15-29 m L/min: reduce dose by 50% (e.g., start 50 mg daily). For Cr Cl <15 m L/min: not recommended. Hemodialysis: administer dose after dialysis on dialysis days; reduce dose by 70%.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
For Child-Pugh Class A (mild): no adjustment. For Child-Pugh Class B (moderate): reduce dose by 50% (e.g., start 50 mg daily). For Child-Pugh Class C (severe): not recommended (or maximum 50 mg daily with caution).
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Safety and efficacy not established in pediatric patients (<18 years). No recommended dosage.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
For patients ≥65 years: initiate at 100 mg daily. Use caution and monitor for confusion and sedation. Consider reducing dose to 50 mg daily if tolerability issues arise.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children); ultra-rapid metabolism of tramadol to O-desmethyltramadol (M1) in CYP2D6 poor metabolizers leading to toxicity; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Respiratory depression; seizure risk (especially with CNS depressants, MAOIs, SSRIs, SNRIs); serotonin syndrome; increased intracranial pressure; severe hypotension; head injury; acute abdominal conditions; renal/hepatic impairment; elderly; debilitated patients; drug dependence; withdrawal; pregnancy; nursing mothers; CYP2D6 ultrarapid metabolizers; concomitant use with alcohol or other CNS depressants.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypersensitivity to tramadol, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; gastrointestinal obstruction (including paralytic ileus); use of MAOIs within 14 days; treatment of acute severe asthma exacerbation; concurrent use of linezolid; known history of prolonged QT interval or QT prolongation risk factors (tramadol component); severe hepatic impairment (acetaminophen).
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Grapefruit and grapefruit juice may increase tramadol levels by inhibiting CYP3A4 metabolism. Avoid excessive caffeine as it may increase seizure risk. Food does not significantly affect absorption; may be taken with or without food.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studies; human data limited but not excluded. In second and third trimesters, prolonged use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). Near term, use may lead to respiratory depression in the neonate.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Tramadol is excreted into breast milk. M/P ratio approximately 0.94 for tramadol and 0.8 for O-desmethyltramadol (active metabolite). Infant exposure estimated at 2.24% of maternal weight-adjusted dose. May cause drowsiness or poor feeding in infants; not recommended during breastfeeding unless benefit outweighs risk.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No specific dose adjustment guidelines; pregnancy may increase clearance of tramadol, potentially reducing efficacy, but safety data insufficient to recommend dose increase. Use lowest effective dose for shortest duration. Chronic use may require slow taper to prevent withdrawal.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
CONZIP (tramadol hydrochloride) is a centrally acting opioid analgesic with additional serotonin and norepinephrine reuptake inhibition. It has a lower risk of respiratory depression compared to typical opioids but carries risks of seizures, especially in patients with epilepsy, head trauma, or those taking SSRIs, SNRIs, or MAOIs. CYP2D6 poor metabolizers may have reduced efficacy. Do not exceed 400 mg/day (300 mg in elderly >75 years). Avoid sudden discontinuation to prevent withdrawal syndrome.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol, sedatives, and other CNS depressants as they increase risk of severe drowsiness and respiratory depression.,Do not stop suddenly; taper dose under medical supervision to prevent withdrawal symptoms.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Risk of serotonin syndrome when combined with other serotonergic drugs; report symptoms like agitation, high fever, or muscle twitching.,If you have a history of seizures, inform your doctor; tramadol may lower seizure threshold.,Swallow tablets whole; do not crush, chew, or split extended-release tablets.,Store in original container away from moisture and heat.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONZIP vs ALFENTA, answered by our medical review team.
CONZIP is a Opioid Analgesic that works by Tramadol hydrochloride (opioid agonist) and acetaminophen (centrally acting analgesic). Tramadol binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake; acetaminophen inhibits cyclooxygenase (COX) and activates descending serotonergic pathways.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONZIP and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONZIP is: 100 mg to 300 mg orally once daily with food. Initiate at 100 mg daily and titrate up by 100 mg increments every 4-7 days based on tolerability. Maximum dose 300 mg daily.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONZIP and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONZIP is classified as Category C. CONZIP (tramadol hydrochloride) is FDA Pregnancy Category C. In first trimester, cross-reactivity with opioid receptors raises concern for neural tube defects based on animal studi. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.